PROSPER study design reported in Hepatology Medicine and Policy of Rifaximin-alpha a proposed treatment for Hepatic Encephalopathy.

Norgine B.V. announced the publication of the study design of PROSPER (The Prospective Real-world Outcomes Study of Hepatic Encephalopathy Patients’ Experience on Rifaximin-alpha ) in the journal Hepatology Medicine and Policy. The study has been designed to monitor the clinical effectiveness of rifaximin-alpha and its impact on health care resources utilisations. PROSPER is an observational, multicentre study among 550 patients in Europe and Australia. Hepatic encephalopathy places a significant burden on patients and their caregivers, with the burden increasing as the severity of the disease progresses. Furthermore patients with hepatic encephalopathy have significantly more hospitalisations, emergency hospital admissions, and primary care contacts compared with patients with severe liver disease without hepatic encephalopathy.

PROSPER will provide valuable real-world information on the effectiveness of rifaximin-alpha 550 mg in reducing the recurrence of hepatic encephalopathy, and its impact on the quality of life (QoL) and work productivity of patients and their caregivers. By providing data on both the direct costs (e.g., hospitalisation rate, duration of hospitalisation) and indirect costs (such as work productivity) of hepatic encephalopathy. PROSPER study findings are anticipated to report in 2018.

See- "Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-alpha (PROSPER): an observational study among 550 patients."- Aleksander KragEmail author, Marcus Schuchmann, Hanna Sodatonou, Jeff Pilot, James Whitehouse, Simone I. Strasser and Mark Hudson Hepatology, Medicine and Policy20183:4 https://doi.org/10.1186/s41124-017-0029-9© .2017 Published: 8 January 2018.